My methodology for selecting pharmaceutical companies with the best risk/reward ratio Before I move on to discuss the global oncology drugs ... factors driving up its share price.

Late-stage trials showed that Tecentriq combined with lurbinectedin led to a 46% reduction in the risk of the disease ...

Every day, manufacturers continue to develop new, life-saving cancer treatments ... as large pharmaceutical manufacturers while adding the advantages of scalability, speed, and risk sharing.

However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...

Itovebi won US Food and Drug Administration (FDA) approval in this breast cancer indication based on INAVO120’s data late ...

Elinzanetant proved effective for managing disruptive vasomotor symptoms in women on endocrine therapy, supporting a Bayer ...

In fact, Zejula was linked to a 1% higher risk of death ... that have an ovarian cancer indication, pharma&’s Rubraca is the smallest player by market share. The Austrian company took over ...

Investors seeking the next breakthrough in precision oncology may want to take note of Nuvectis Pharma (NASDAQ ... Nuvectis represents a high-risk, high-reward opportunity typical of early ...

Big Pharma will hunt for more acquisitions in 2025 as industry giants face patent expiration for some of their best-selling drugs, according to a top M&A banker. Merck's cancer drug Keytruda ...

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients ... please refer to the Risk Factors (“Facteurs de Risque") section of ...

Isabel joined Newsweek in July 2024, after covering the pharmaceutical ... share unique social, economic, political, and climate environments, which affect their exposure to cancer risk factors ...